| Expression pattern: |
DN |
| Associated gene: |
FOXO1, AGO2, p27kip1, p21cip1 |
| Associated microRNA: |
miR-4793-3p |
| Biological function: |
Suppresses gastric cancer cell proliferation and retards/block cell cycle progression (G1/S); acts as a tumor suppressor in GC. |
| Molecular mechanism: |
ceRNA mechanism: circEVI5 sponges miR-4793-3p to relieve repression of FOXO1, increasing FOXO1 (and downstream p27kip1/p21cip1) expression and causing G1 arrest. |
| Biological pathway or process: |
proliferation (inhibits); cell cycle (inhibits); ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Sanger Sequencing; FISH / smFISH; Clinical Sample Validation; Survival Analysis; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Cell Cycle Assay; Western Blot; In Vivo Animal Model; RNA-seq |
| Clinical significance: |
Low circEVI5 expression in GC tissues correlates with poor relapse-free survival (RFS) and may be an appropriate biomarker. |
| Description: |
circEVI5 is down-regulated in gastric cancer tissues/cells and functions as a tumor suppressor by inhibiting proliferation and inducing G1/S arrest. Mechanistically, it sponges miR-4793-3p to de-repress FOXO1 (and increase p21cip1/p27kip1), and low circEVI5 expression is associated with poorer relapse-free survival. |
| Confidence score: |
0.853 |